CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

Cambridge Cognition signs new eCOA contracts

Cambridge Cognition today announced it has won a significant new phase IV clinical trial contract for use of its electronic clinical outcomes assessment (eCOA) platform, CANTAB Connect.

Three ways you can design better drug trials for schizophrenia therapeutics

To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.                                                                                                                                                                                                  

How can you measure behavior more accurately in your clinical trials?

Drug development typically relies upon clinical endpoints established within very controlled laboratory environments. Digital health technologies now provide the opportunity to transition data collection from the clinic into people’s personal lives, thereby providing more accurate conclusions about how a compound can influence their day-to-day life. 

Does using digital health in clinical trials generate real-world outcomes?

High-frequency digital health assessments can not only characterize clinically-relevant data as it occurs in real-time, but capture this information within the patient’s home environment. Therefore, digital health platforms provide an ecologically valid data source which directly maps on to an individual’s daily functioning and real-world outcomes. 

Can digital health reduce the treatment burden on patients?

Comprehensive neuropsychological testing typically takes hours to complete, which can be mentally and physically burdensome for patients. Furthermore, the travel required and overall time-commitment to undergo these procedures within a clinic can result in decreased study compliance. Together these factors can confound conclusions concerning treatment efficacy. Here we will discuss how digital health can reduce these burdens when implementing therapeutic interventions to improve patient outcomes. 

Four reasons to use digital health in your clinical trials

In the first of our digital health series we will outline what the term means, and the opportunities offered, within the context of clinical trials in psychiatry. 

How can digital health improve the signal-to-noise ratio in your clinical trials?

The contemporary framework for designing clinical trials is to build a comprehensive cognitive profile of the patient population from thorough but infrequent assessments. However, this framework struggles to capture the daily fluctuations in mood and cognition that many individuals with psychiatric disorders experience. Here we will discuss how the advent of digital health offers the opportunity to capture a more holistic representation of patients’ cognitive function from high-frequency assessments.

A solution for improving recruitment into early Alzheimer’s disease clinical trials

Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials. 

CANTAB Recruit software to be used in two major Phase III drug trials

​We’re pleased to announce that our CANTAB Recruit software is now established in two major Phase III trials into Alzheimer’s disease.

The challenge of detecting early Alzheimer’s disease for clinical trials

In this post, Director of Clinical Affairs, Dr Kenton Zavitz, looks at the challenge of recruiting the correct patients into Alzheimer's disease trials.

Exploring participant-level trajectories of cognitive performance in patients with schizophrenia

Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.

What does the new FDA guidance mean for clinical trials in early Alzheimer’s disease?

The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development. 

WEBINAR: Finding the right patients for clinical trials in early Alzheimer's disease

Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, hosted a webinar to discuss clinical trials for early Alzheimer’s disease.

Join them to hear more about overcoming the barriers to expedite the drug development process.

Tuesday 22nd May 2018, 11 a.m. EDT

Can acetylcholinesterase inhibitors and CNS stimulants tackle cognitive dysfunction in multiple scle

Cognitive dysfunction in multiple sclerosis (MS) presents a significant, unmet therapeutic need. Researchers at Cambridge Cognition and the University of Manchester investigated potential solutions to this problem with a systematic review and meta-analysis of pro-cognitive drug trials in MS. 

Trial design: 4 ways to improve trials of pro-cognitive drugs in schizophrenia

Discussing the methodological considerations, and suggesting recommendations, for successful pro-cognitive drugs trials in schizophrenia.

Patient recruitment: are you selecting the right patients for schizophrenia clinical trials?

The importance of recruiting patients for pro-cognitive drug trials in schizophrenia on the basis of cognitive dysfunction. 

Improving clinical trials for pro-cognitive drugs in schizophrenia

Introducing a blog-post series to discuss key limitations, and potential improvements, for pro-cognitive drug trials in schizophrenia.

WEBINAR: Overcoming methodological challenges to enhance study success in schizophrenia trials

Dr Kiri Granger, Director of Neuroscience, Cambridge Cognition and Dr Steve Brannan, Chief Medical Officer, ‎Karuna Pharmaceuticals Inc. hosted a webinar on how to improve clinical trial success in schizophrenia.

Speech recognition and online assessments: the future for clinical trials in Alzheimer's disease?

New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.

The CANTAB Paired Associates Learning task as a pre-screening tool for clinical trials

Enriching participant eligibility for clinical trials through pre-screening for cognitive deficit.

Pre-Screening for Episodic Memory Deficits To Enrich Recruitment in Alzheimer's Disease Trials

Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?

Using defined inclusion criteria to establish baseline cognitive deficits in CIAS clinical trials

Dr Kiri Granger presented this poster at the International Congress on Schizophrenia Research on the 25th March 2017.